MWA
NKTR icon

Medallion Wealth Advisors’s Nektar Therapeutics NKTR Stock Holding History

Medallion Wealth Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$935 Hold
13
– – ﹤0.01% 1063
2025
Q4 		$550 Hold
13
– – ﹤0.01% 1072
2025
Q3 		$740 Hold
13
– – ﹤0.01% 1049
2025
Q2 		$336 Sell
13
-1
-7% -$11 ﹤0.01% 1058
2025
Q1 		$141 Hold
14
– – ﹤0.01% 1048
2024
Q4 		$141 Buy
+14
New +$247 ﹤0.01% 991

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Medallion Wealth Advisors's NKTR Position: Q1 2026 in Review

Medallion Wealth Advisors held its Nektar Therapeutics (NKTR) position steady in Q1 2026 at 13 shares worth $935. The position accounts for ﹤0.01% of the portfolio, ranked #1063.

Medallion Wealth Advisors first reported a position in NKTR in Q4 2024 and has held it in 6 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Medallion Wealth Advisors held 13 shares of Nektar Therapeutics worth $935 as of Q1 2026.
  • Medallion Wealth Advisors left its Nektar Therapeutics share count unchanged in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of Medallion Wealth Advisors's portfolio in Q1 2026, its #1063 holding.
  • Medallion Wealth Advisors first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Medallion Wealth Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.